RIGL earnings analysis
What we found in RIGL's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Rigel's Q2 underlying commercial performance improved: net product sales rose to $67.0 million, led by TAVALISSE and REZLIDHIA, and total revenue rebounded sequentially to $78.7 million. Reported revenue nevertheless fell $23.0 million year over year because Q2 2025 included a $40.0 million non-cash Lilly collaboration item that did not recur. The company generated $33.4 million of six-month operating cash flow, but cash declined to $95.3 million following the $70.0 million VEPPANU upfront license payment and related investment; the mid-August VEPPANU launch is the principal near-term upside catalyst and execution risk.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Sequential revenue recovery, distorted YoY comparison
- Q2 revenue was $78.7 million, up approximately 33% sequentially from $59 million in Q1 2026, but down $23.0 million year over year from $101.7 million. The year-over-year decline principally reflects the absence of a $40.0 million non-cash Lilly collaboration revenue item in Q2 2025.
- Core product portfolio grew 14%
- Net product sales increased $8.1 million year over year to $67.0 million. TAVALISSE grew 18% to $47.4 million and REZLIDHIA grew 27% to $8.9 million, more than offsetting GAVRETO's 10% decline to $10.7 million.
- Still-high margins despite cost normalization
- Gross profit was $70.2 million on $78.7 million of revenue and $8.5 million of product costs, implying an 89.2% gross margin. Operating income was approximately $23.6 million after $14.0 million of R&D and $32.6 million of SG&A, or a 30.0% operating margin.
- Operating cash generation remained positive
- Six-month operating cash flow increased to $33.4 million from $29.6 million a year earlier. Liquidity included $95.3 million of cash, cash equivalents and short-term investments at June 30, and management states existing resources support projected requirements for at least the next 12 months.
- VEPPANU launch creates a new growth vector
- VEPPANU is expected to become commercially available in mid-August 2026. The licensed breast-cancer product addresses an estimated 20,000 eligible US second- or third-line patients, and its pivotal ESR1-mutated cohort showed a 43% reduction in risk of progression or death versus fulvestrant.
- R289 has late-2026 clinical catalysts
- Management expects to complete R289 dose-expansion enrollment and select a recommended Phase 2 dose in the second half of 2026, with preliminary data anticipated by year-end 2026. The study is expected to enroll approximately 86 patients.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- VEPPANU economics and transition execution risk
- VEPPANU requires a $70.0 million upfront payment already paid, up to $15.0 million more for transition activities, up to $60.0 million in regulatory milestones and up to $260.0 million in commercial milestones. Rigel also must reimburse ongoing development costs up to an aggregate $40.0 million through 2029; transition, supply, access and adoption execution remain unproven ahead of launch.
- Cash drawdown and borrowing-base liquidity risk
- Cash, cash equivalents and short-term investments fell $59.7 million from $155.0 million at December 31, 2025 to $95.3 million at June 30, 2026. The new MidCap revolver had $40.0 million drawn at quarter-end, is secured by substantially all assets, and has a variable rate of one-month SOFR plus 4.00%; $32.0 million was repaid in July, leaving $8.0 million outstanding.
- Potential 100% pharmaceutical tariff exposure
- A newly highlighted tariff risk could raise product costs: the April 2, 2026 proclamation imposes a 100% ad valorem tariff on patented pharmaceutical imports and associated ingredients for smaller importers from September 29, 2026. Although all three commercial products have orphan designation, qualification for the potential 0% exemption remains uncertain.
- GAVRETO volume and regulatory pressure
- GAVRETO sales declined 10% year over year to $10.7 million due to lower volumes and higher revenue reserves. Its label added a boxed warning for serious and opportunistic infections in December 2025, while confirmatory requirements for the thyroid-cancer accelerated-approval indication remain under discussion with FDA.
- Loss of Lilly collaboration income
- Lilly terminated its collaboration effective June 15, 2026, and Rigel does not expect future milestones or royalties under that agreement. This follows a $40.0 million non-cash collaboration-revenue benefit recorded in Q2 2025, helping explain collaboration revenue falling to $11.7 million from $42.7 million.
What they reported.
What the company itself reported, taken out of the document.
- Gross margin
- 89.2%
- Operating margin
- 30.0%
- Segment
- TAVALISSE net product sales: $47.4 million, up 18% year over year from $40.1 million.
- Segment
- REZLIDHIA net product sales: $8.9 million, up 27% year over year from $7.0 million.
- Segment
- GAVRETO net product sales: $10.7 million, down 10% year over year from $11.8 million.
- Segment
- Collaboration and other revenue: $11.7 million, down from $42.7 million, reflecting the prior-year $40.0 million non-cash Lilly cost-share-liability release.
What they said about what is next.
The 10-Q provides no quantitative revenue or EPS guidance. Management expects product-sales revenue to increase in coming quarters as seasonal reimbursement effects subside and VEPPANU launches in August 2026.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 5, 2026
- Rigel Pharmaceuticals reported Q1 2026 revenue growth of 10.3% year-over-year to $58.8 million, driven by strong product sales including a 31% increase for TAVALISSE and REZLIDHIA. Despite the growth, net income was…
- 10-K · March 3, 2026
- Rigel’s 2025 10-K documents a clear commercial pivot: product sales grew materially in 2025 with TAVALISSE net sales of $158.8 million (up 51.6% vs. $104.8M in 2024), REZLIDHIA $31.0 million (up 34.8% vs. $23.0M) and…
- 10-Q · August 5, 2025
- Rigel reported a strong Q2 2025 with total revenue of $101.685M and GAAP net income of $59.613M, producing diluted EPS of $3.28. Revenue growth was driven by product sales of $58.948M and a $39.981M release of a…
- 10-Q · May 6, 2025
- Rigel reported Q1 2025 revenue of $53,333 (thousands) and GAAP net income of $11,446 (thousands), producing diluted EPS of $0.63. Revenue grew 80.6% year-over-year (from $29,534) driven by product sales ($43,550) and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing RIGL makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever